To date, few approaches have found clinical success to meet the rigor of USFDA approval – such as the use of the anti VEGF agent lenvatinib (in combination with pembrolizumab in patients with renal (63) and endometrial cancer (64), and bevacizumab (with atezolizumab for patients with hepatocellular cancer (65). The gene discussed is VEGFA; the disease is hepatocellular carcinoma.